Madison Vaccines Says Report On Early Findings From MVI-118 Clinical Trial Selected For Presentation By The Prostate Cancer Foundation
Analysis of Initial patients to be Presented at the Annual Prostate Cancer Foundation Retreat, October 27th
Madison, WI, October 25, 2016 – Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, says initial analysis of the first 13 patients enrolled in the MVI-118 clinical trial shows acceptable safety and tolerability, and enhanced patient immune response to the AR antigen encoded by the vaccine. The human androgen receptor is the critical biological target that drives the progression of prostate cancer and, in many cases, is responsible for the resistance to current therapies. MVI-118 is being developed to prolong the duration of disease control gained from standard hormone deprivation therapies. The findings will be presented at the annual Prostate Cancer Foundation Scientific Retreat, October 27, in Carlsbad, CA, just north of San Diego.
The Phase 1 MVI-118 study is an investigator-sponsored clinical trial being run by the University of Wisconsin-Madison under the overall direction of Douglas McNeel, MD, PhD. whose laboratory developed the vaccine. Brian Olson, PhD, a former graduate student and clinical researcher at UW-Madison, was provided with a PCF Young Investigator Award that included conducting immunological analyses of patient samples from the MVI-118 Phase 1 clinical trial. According to the publicly released abstract Olson’s analysis of just the first 13 patients enrolled in the trial demonstrate that intradermal immunization of these metastatic prostate cancer patients with MVI-118 resulted in no significant adverse events, regardless of the schedule of administration, while enhancing antigen-specific immune responses.
"Although these are very early findings, it is encouraging any time we get news that one of our treatments may be helping in the fight against prostate cancer," says Richard Lesniewski, PhD, President of MVI. "Madison Vaccines is also very proud of Brian Olson’s recognition and we look forward to even more promising clinical evidence as the Phase 1 trial progresses."
The MVI-118 trial is underway at the University of Wisconsin-Madison Carbone Cancer Center, with enrollment beginning at a second trial-site at the Cancer Institute of New Jersey (CINJ-Rutgers).
This is the second recognition of research related to the MVI vaccines by the Prostate Cancer Foundation. In 2014, a $1.5 million award funded by the Movember Foundation and supported by the Movember-PCF Challenge Award program was presented to Dr. McNeel’s laboratory for the study of MVI’s lead vaccine, MVI-816, in a combination approach to immunotherapy. Emerging data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in November.
The principal mission of Madison, Wisconsin-based MVI is the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. Plasmid vaccines can be rapidly and inexpensively purified, are relatively more stable in storage, and don’t have to be tailored to each individual patient. MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison. More information is available at www.madisonvaccines.com.
Corporate: Richard Lesniewski, PhD, President, Madison Vaccines Incorporated, (610) 850-4697
Media: Peggy Frank, Initiate PR, (818) 735-3591